NCT02318394 - A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2015

Primary Completion Date

January 9, 2018

Study Completion Date

January 9, 2018

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

MEDI0562

Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.

Trial Locations (12)

Research Site, New York

Research Site, The Bronx

Research Site, Pittsburgh

Research Site, Huntersville

Research Site, Ann Arbor

Research Site, Detroit

Research Site, Minneapolis

Research Site, Dallas

Research Site, Houston

Research Site, La Jolla

Research Site, Portland

Research Site, Seoul